← Signals · Healthcare · TSXV
$PAIN
Vector Science and Therapeutics Corp.
Signal as of August 19, 2026  ·  90-day rolling window  ·  Biotechnology & Life Sciences
Confluence Score
45
out of 100  ·  Full breakdown →
Score delayed 7 days on Free  ·  See today's score — Analyst →
Signals scoring 40–59 have historically hit 41% of the time (avg +7.1% over 90 days, 4424 backtested signals). Methodology →
🔒 Risk monitoring — insider-selling & reversal warnings (Analyst)
📅 Buying into earnings — Aug 28 (2d)
Confluence Score
45
Insider Activity (90d)
1
1 buyer  ·  $4K  ·  open-market only
Current Price
$1.91
CAD  ·  5-min cache
Market Cap
$299M
CAD  ·  TMX
Lobbying & Contracts
None
0 regs  ·  0 contracts
Healthcare on Form55: 43% hit rate · -5.4% alpha vs XIU.TO · 21 closed signals Track Record →
Signal Analyst
The Confluence Score and insider trade feed above are free. Signal Analyst adds the full component breakdown, lobbying registrations, and contract wins — plus alerts when this company's signal moves, so you don't have to keep checking back.
Monitor — CAD $29/mo
Price Chart
12 months daily  ·  TSXV:PAIN
Insider Transactions
90-day window  ·  4 filings
Date Insider Role Nature Dir. Shares Buy Price Return Value
Jul 13, 2026 Dobranowski, Alexander Julian Open Market Buy 2,000 $2.18 -12.4%  · 44d $4K
May 29, 2026 Dobranowski, Alexander Julian Comp. Grant Buy 68,870
May 29, 2026 Thompson, Tommy George Comp. Grant Buy 68,870
May 29, 2026 Kelly, Scott Comp. Grant Buy 68,870 $1.69 +13.0%  · 89d $116K
Score uses open-market buys only  ·  1 open-market  ·  3 plan / compensation shown but not scored  ·  Return is unrealized, to today's price; a “· Nd” mark means the 90-day window is still open (N of 90 days) — too early to judge.
Score Breakdown
Signal Analyst  ·  $29/mo
Component Points Max Detail Weight
Conviction (unique buyers)  ✓ FREE PREVIEW 30 30 1 unique buyer (maximum conviction)
Buy/sell ratio 20 50% buys (1B / 1S)
Dollar value 25 $4K
Lobbying activity 15 None
Contract wins 10 None
Insider track record 10 No track record data
Private placements 8 None
Confluence bonus 10 None
Cluster timing (velocity) 10 No coordinated buying cluster detected
Buy/sell reversal pattern 8 No buy/sell reversal pattern
Total 45 100
Unlock Component Detail — CAD $29/mo
Buying Insiders
Open-market · 90 days · 1 unique buyer
Insider Credibility Hit Rate Avg 90d Return Trades (eval'd) Buy Value (90d) Last Buy
Dobranowski, Alexander Julian $4K Jul 13, 2026
Credibility score: historical hit rate × avg 90d return × sample size. View full insider leaderboard →
Lobbying Registrations
OCL active  ·  none found
No active OCL lobbying registrations in the last 90 days. Analyst plan →
Government Contract Wins
90-day window  ·  none found
No government contract wins in the last 90 days. Analyst plan →
Private Placements
12 months  ·  Signal Analyst  ·  $29/mo
Private placement history, deal size, and lock-up expiry tracking. Analyst plan →
Indigenous Consultation
no records on file

No Indigenous consultation records on file for PAIN.

SEDAR+ Filings
official filing registry
Form55 monitors SEDAR+ filing alerts and newswire announcements for Technical Reports and material changes. Search SEDAR+ →
Short Interest
CIRO  ·  Aug 15, 2026
Shares short
303,772
Net change
+178,998 (+143.5%)
Short interest rose 143% since the prior report.
History
Aug 15: 303,772
Jul 31: 124,774
Jul 15: 169,817
Jun 30: 106,400
Jun 15: 138,534
May 31: 10,353
Aggregate short position from CIRO's Consolidated Short Position Report (published twice monthly).
Boardroom Connections
2 insiders also active elsewhere
Insider Other boards Also an insider at
Kelly, Scott 4 CLV (65), WEB, DRY, SPMC
Dobranowski, Alexander Julian 1 AIDX
People who file as insiders here and at other TSX/TSXV companies (number in brackets = that company's Confluence Score). A well-connected insider taking a seat at a new junior can be an early tell. Matched by name across SEDI filings; funds and 10%+ holders excluded.
Form55 provides data and analysis for informational purposes only. Nothing on this site constitutes investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.